Cartesian Therapeutics Statistics
Total Valuation
RNAC has a market cap or net worth of $204.65 million. The enterprise value is $73.87 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RNAC has 26.00 million shares outstanding. The number of shares has increased by 111.41% in one year.
| Current Share Class | 26.00M |
| Shares Outstanding | 26.00M |
| Shares Change (YoY) | +111.41% |
| Shares Change (QoQ) | -1.68% |
| Owned by Insiders (%) | 58.38% |
| Owned by Institutions (%) | 25.63% |
| Float | 9.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 186.44 |
| Forward PS | 269.49 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 67.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.67
| Current Ratio | 10.67 |
| Quick Ratio | 10.44 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -12.67% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -23.38% |
| Revenue Per Employee | $16,530 |
| Profits Per Employee | -$726,955 |
| Employee Count | 66 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RNAC has paid $287,000 in taxes.
| Income Tax | 287,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.27% in the last 52 weeks. The beta is 0.39, so RNAC's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -62.27% |
| 50-Day Moving Average | 9.43 |
| 200-Day Moving Average | 12.26 |
| Relative Strength Index (RSI) | 36.10 |
| Average Volume (20 Days) | 156,580 |
Short Selling Information
The latest short interest is 2.12 million, so 8.17% of the outstanding shares have been sold short.
| Short Interest | 2.12M |
| Short Previous Month | 2.24M |
| Short % of Shares Out | 8.17% |
| Short % of Float | 22.62% |
| Short Ratio (days to cover) | 25.20 |
Income Statement
In the last 12 months, RNAC had revenue of $1.09 million and -$47.98 million in losses. Loss per share was -$1.87.
| Revenue | 1.09M |
| Gross Profit | -30.93M |
| Operating Income | -83.92M |
| Pretax Income | -47.69M |
| Net Income | -47.98M |
| EBITDA | -81.08M |
| EBIT | -83.92M |
| Loss Per Share | -$1.87 |
Full Income StatementBalance Sheet
The company has $143.38 million in cash and $12.60 million in debt, giving a net cash position of $130.78 million or $5.03 per share.
| Cash & Cash Equivalents | 143.38M |
| Total Debt | 12.60M |
| Net Cash | 130.78M |
| Net Cash Per Share | $5.03 |
| Equity (Book Value) | -35.84M |
| Book Value Per Share | -1.38 |
| Working Capital | 133.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$63.23 million and capital expenditures -$5.67 million, giving a free cash flow of -$68.90 million.
| Operating Cash Flow | -63.23M |
| Capital Expenditures | -5.67M |
| Free Cash Flow | -68.90M |
| FCF Per Share | -$2.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -7,691.84% |
| Pretax Margin | -4,371.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -111.41% |
| Shareholder Yield | -111.41% |
| Earnings Yield | -23.44% |
| FCF Yield | -33.67% |
Analyst Forecast
The average price target for RNAC is $40.00, which is 408.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.00 |
| Price Target Difference | 408.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 18.80% |
| EPS Growth Forecast (5Y) | -8.90% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 5, 2024. It was a reverse split with a ratio of 1:30.
| Last Split Date | Apr 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |
